TY - JOUR T1 - Two New Models for Epidemics with Application to the COVID-19 Pandemic in the United States, Italy, and the United Kingdom JF - medRxiv DO - 10.1101/2020.07.13.20152686 SP - 2020.07.13.20152686 AU - David H. Roberts Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/14/2020.07.13.20152686.abstract N2 - The Distributed Logistic Model and the Adaptive Logistic Model of epidemics are formulated and used to study the course of cases and deaths during the COVID-19 pandemic. The distributed model is designed to account for a spread of initiation times of hot spots across a country; it does especially well at capturing the initial and linear phases of epidemics. The adaptive model accounts for the development of social mitigation factors, and does especially well at capturing the declining phases of epidemics. The historical data for the U.S., Italy, and the U.K. are analyzed in detail. The parameters of the fits to the two models provide complementary information about the pandemic. The initial infection rate constant was r0 ≃ 0.29 day−1 for each country, and the effective infection rate constants evolved with time in essentially the same way for each. This suggests that mitigation effects were equally effective in all three countries. Analysis with the distributed model suggests that it took somewhat different times T for the epidemic to spread across each country, with T (US)≃ 50 days significantly greater than the T ‘s of Italy or the U.K. The mortality ratio in the U.S. was about 0.061 while in Italy and U.K. it was much larger at about 0.15.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study did not involve a clinical trial.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code used in this study are available to any person. ER -